Article(id=1327672224779187067, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327672185726022203, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2022.10.005, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1646755200000, receivedDateStr=2022-03-09, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794471325344, onlineDateStr=2026-11-12, pubDate=1665331200000, pubDateStr=2022-10-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794471325344, onlineIssueDateStr=2026-11-12, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794471325344, creator=13701087609, updateTime=1794471325344, updator=13701087609, issue=Issue{id=1327672185726022203, tenantId=1146029695717560320, journalId=1319690259887390882, year='2022', volume='53', issue='10', pageStart='1377', pageEnd='1528', issueExtLink='null', onlineDate='null', pubDate='1665331200000', pubDateStr='2022-10-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794471316033, creator='13701087609', updateTime=1794472113883, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1327675532587676595, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327672185726022203, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1327675532587676596, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327672185726022203, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1408, endPage=1418, ext={EN=ArticleExt(id=1327672224980513660, articleId=1327672224779187067, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Small Molecule JAK Inhibitors for the Treatment of Myelofibrosis and Its Patent Research, columnId=1327671134809600231, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Review, runingTitle=null, highlight=null, articleAbstract=
Three small molecule JAK inhibitors, namely ruxolitinib phosphate, fedratinib hydrochloride, and pacritinib citrate, for the treatment of myelofibrosis have been marketed worldwide. Their research progress and the published patents on chemical compound, crystalline form, salt form, process, formulation, drug combination, new use, and product derivatives, as well as the compounds in pharmaceutical research are unscrambled and researched in this paper. It is hoped to provide patent information and reference for Chinese pharmaceutical companies conducting project establishment and development, new patent mining, patent protection, and patent layout.
, authors=Lu HUANG
1, 2, 3, Jian SUN
4, Mingwei WANG
5, Fan GE
6, *, authorsList=Lu HUANG, Jian SUN, Mingwei WANG, Fan GE, authorCompany=null, correspAuthors=Fan GE, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1327672225450275709, articleId=1327672224779187067, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=用于治疗骨髓纤维化的小分子JAK抑制剂及其专利研究, columnId=1327671135019315436, journalTitle=中国医药工业杂志, columnName=综述, runingTitle=null, highlight=null, articleAbstract=
该研究梳理了全球已获批上市和正在研发中的用于治疗骨髓纤维化的小分子JAK抑制剂药物品种情况,对其中3个重点药物磷酸芦可替尼、盐酸菲卓替尼、枸橼酸帕克替尼的研发进展,以及涉及其化合物、晶型、盐型、工艺、药物制剂、药物组合物、新用途和衍生物等不同技术主题的已公开专利进行研究和分析,以期为医药企业在进行有关药物的立项与开发、新的专利挖掘、专利保护及专利布局时,提供有效的产品信息和专利信息等参考。
, authors=黄璐
1, 2, 3, 孙建
4, 王明伟
5, 葛凡
6, *, authorsList=黄璐, 孙建, 王明伟, 葛凡, authorCompany=null, correspAuthors=葛凡, authorNote=
黄璐(1982—),男,高级工程师,从事药物研发与医药知识产权工作。
, correspAuthorsNote=
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=ogqutt3Lxy/qNCLszbb2hA==, magXml=1pOap/YyLHpOQPq8izR4nA==, pdfUrl=null, pdf=RsspWjj7xciMyt5g2NqR6A==, pdfFileSize=2060431, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=OWx3DcH1UFZt5IL1M4c8Og==, mapNumber=null, fund=null)}, authors=[Author(id=1327672226087809937, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327672226167501717, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, authorId=1327672226087809937, language=EN, stringName=Lu HUANG, firstName=Lu, middleName=null, lastName=HUANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, 2, 3, address=
1.School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205
2.School of Pharmacutical Sciences, Wuhan University, Wuhan 430071
3.Guangzhou Wellhealth Bio-pharma Co., Ltd., Guangzhou 510200, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327672226230416278, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, authorId=1327672226087809937, language=CN, stringName=黄璐, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, 2, 3, address=
1.武汉工程大学化工与制药学院,湖北 武汉 430205
2.武汉大学药学院,湖北 武汉 430071
3.广州丹康医药生物有限公司,广东 广州 510200, bio={"content":"
黄璐(1982—),男,高级工程师,从事药物研发与医药知识产权工作。
"}, bioImg=null, bioContent=
黄璐(1982—),男,高级工程师,从事药物研发与医药知识产权工作。
, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327672225651602302, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, xref=1., ext=[AuthorCompanyExt(id=1327672225659990911, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225651602302, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205), AuthorCompanyExt(id=1327672225668379520, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225651602302, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.武汉工程大学化工与制药学院,湖北 武汉 430205)]), AuthorCompany(id=1327672225727099777, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, xref=2., ext=[AuthorCompanyExt(id=1327672225735488386, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225727099777, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.School of Pharmacutical Sciences, Wuhan University, Wuhan 430071), AuthorCompanyExt(id=1327672225739682691, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225727099777, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.武汉大学药学院,湖北 武汉 430071)]), AuthorCompany(id=1327672225785820036, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, xref=3., ext=[AuthorCompanyExt(id=1327672225794208645, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225785820036, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
3.Guangzhou Wellhealth Bio-pharma Co., Ltd., Guangzhou 510200), AuthorCompanyExt(id=1327672225802597254, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225785820036, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
3.广州丹康医药生物有限公司,广东 广州 510200)])]), Author(id=1327672226301719448, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327672226398188442, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, authorId=1327672226301719448, language=EN, stringName=Jian SUN, firstName=Jian, middleName=null, lastName=SUN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
4, address=
4.Kanazawa Institute of Technology, Tokyo 105-0002, Japan, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327672226469491611, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, authorId=1327672226301719448, language=CN, stringName=孙建, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
4, address=
4.金泽工业大学大学院,日本 东京都 105-0002, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327672225848734599, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, xref=4., ext=[AuthorCompanyExt(id=1327672225857123208, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225848734599, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
4.Kanazawa Institute of Technology, Tokyo 105-0002, Japan), AuthorCompanyExt(id=1327672225861317513, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225848734599, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
4.金泽工业大学大学院,日本 东京都 105-0002)])]), Author(id=1327672226532406173, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327672226624680863, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, authorId=1327672226532406173, language=EN, stringName=Mingwei WANG, firstName=Mingwei, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
5, address=
5.Dept. of Pathology, Hubei Cancer Hospital, Wuhan 430079, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327672228323373984, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, authorId=1327672226532406173, language=CN, stringName=王明伟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
5, address=
5.湖北省肿瘤医院病理科,湖北 武汉 430079, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327672225920037770, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, xref=5., ext=[AuthorCompanyExt(id=1327672225928426379, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225920037770, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
5.Dept. of Pathology, Hubei Cancer Hospital, Wuhan 430079), AuthorCompanyExt(id=1327672225936814988, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225920037770, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
5.湖北省肿瘤医院病理科,湖北 武汉 430079)])]), Author(id=1327672228407260066, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=174966496@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1327672228495340452, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, authorId=1327672228407260066, language=EN, stringName=Fan GE, firstName=Fan, middleName=null, lastName=GE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
6, *, address=
6.FIWIS Intellectual Property Law Firm, Beijing 100032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327672228558255013, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, authorId=1327672228407260066, language=CN, stringName=葛凡, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
6, *, address=
6.北京孚睿湾知识产权代理事务所,北京 100032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327672225991340941, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, xref=6., ext=[AuthorCompanyExt(id=1327672225999729550, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225991340941, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
6.FIWIS Intellectual Property Law Firm, Beijing 100032), AuthorCompanyExt(id=1327672226008118159, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225991340941, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
6.北京孚睿湾知识产权代理事务所,北京 100032)])])], keywords=[Keyword(id=1327672228684084134, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, language=EN, orderNo=1, keyword=myelofibrosis), Keyword(id=1327672228755387303, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, language=EN, orderNo=2, keyword=JAK inhibitor), Keyword(id=1327672228814107560, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, language=EN, orderNo=3, keyword=ruxolitinib phosphate), Keyword(id=1327672228881216425, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, language=EN, orderNo=4, keyword=fedratinib hydrochloride), Keyword(id=1327672228952519594, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, language=EN, orderNo=5, keyword=pacritinib citrate), Keyword(id=1327672229019628459, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, language=EN, orderNo=6, keyword=patent research), Keyword(id=1327672229078348716, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, language=CN, orderNo=1, keyword=骨髓纤维化), Keyword(id=1327672229137068973, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, language=CN, orderNo=2, keyword=JAK抑制剂), Keyword(id=1327672229199983534, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, language=CN, orderNo=3, keyword=磷酸芦可替尼), Keyword(id=1327672229258703791, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, language=CN, orderNo=4, keyword=盐酸菲卓替尼), Keyword(id=1327672229330006960, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, language=CN, orderNo=5, keyword=枸橼酸帕克替尼), Keyword(id=1327672229388727217, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, language=CN, orderNo=6, keyword=专利研究)], refs=[Reference(id=1327672229552305075, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=SHUAI K, LIU B.Regulation of JAK-STAT signalling in the immune system [J].
Nat Rev Immunol, 2003,
3(11):900-911., articleTitle=null, refAbstract=null), Reference(id=1327672229611025332, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=HIGASHI Y.JAK inhibitors as a new generation of small-molecule immunosuppressants: JAK-STAT signal control and monitoring [J].
Nihon Yakurigaku Zasshi, 2014,
144(4):160-166., articleTitle=null, refAbstract=null), Reference(id=1327672229665551285, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=KISSELEVA T, BHATTACHARYA S, BRAUNSTEIN J,
et al.Signaling through the JAK/STAT pathway, recent advances and future challenges [J].
Gene, 2002,
285(1/2):1-24., articleTitle=null, refAbstract=null), Reference(id=1327672229745243062, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=AARONSON D S, HORVATH C M.A road map for those who don't know JAK-STAT [J].
Science, 2002,
296(5573):1653-1655., articleTitle=null, refAbstract=null), Reference(id=1327672229824934839, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=王海,屠永锐.针对Janus激酶靶点及其相关抑制剂的研究进展[J].中国医药工业杂志,2021,
52(6):728-741., articleTitle=null, refAbstract=null), Reference(id=1327672229900432312, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=HARRISON C N, SCHAAP N, VANNUCCHI A M,
et al.Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib(JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study [J].
Lancet Haematol, 2017,
4(7): e317-e324., articleTitle=null, refAbstract=null), Reference(id=1327672229954958265, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=CERVANTES F.How I treat myelofibrosis [J].
Blood,2014,
124(17): 2635-2642., articleTitle=null, refAbstract=null), Reference(id=1327672230017872826, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=BAXTER E J, SCOTT L M, CAMPBELL P J,
et al.Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].
Lancet, 2005,
365(9464):1054-1061., articleTitle=null, refAbstract=null), Reference(id=1327672230089175995, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=JAMES C, UGO V, LE COUEDIC J P,
et al.A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].
Nature, 2005,
434(7037):1144-1148., articleTitle=null, refAbstract=null), Reference(id=1327672230152090556, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=KRALOVICS R, PASSAMONTI F, BUSER A S,
et al.A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].
N Engl J Med, 2005,
352(17): 1779-1790., articleTitle=null, refAbstract=null), Reference(id=1327672230215005117, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=LEVINE R L, WADLEIGH M, COOLS J,
et al.Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].
Cancer Cell, 2005,
7(4): 387-397., articleTitle=null, refAbstract=null), Reference(id=1327672230290502590, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=REITER A, INVERNIZZI R, CROSS N C P,
et al.Molecular basis of myelodysplastic/myeloproliferative neoplasms [J].
Haematologica, 2009,
94(12): 1634-1638., articleTitle=null, refAbstract=null), Reference(id=1327672230357611455, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=NANGALIA J, MASSIE C E, BAXTER E J,
et al.Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 [J].
N Engl J Med, 2013,
369(25):2391-2405., articleTitle=null, refAbstract=null), Reference(id=1327672230428914624, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=DEISSEROTH A, KAMINSKAS E, GRILLO J,
et al.U.S.Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis [J].
Clin Cancer Res, 2012,
18(12): 3212-3217., articleTitle=null, refAbstract=null), Reference(id=1327672230487634881, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Clarivate Analytics公司.Cortellis数据库[EB/OL].(2022-05-05)[2022-05-06].
https://www.cortellis.com/intelligence., articleTitle=null, refAbstract=null), Reference(id=1327672230558938050, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=VANNUCCHI A M, KILADJIAN J J, GRIESSHAMMER M,
et al.Ruxolitinib versus standard therapy for the treatment of polycythemia vera [J].
N Engl J Med, 2015,
372(5):426-435., articleTitle=null, refAbstract=null), Reference(id=1327672230626046915, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=KILADJIAN J J, ZACHEE P, HINO M,
et al.Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera(RESPONSE): 5-year follow up of a phase 3 study [J].
Lancet Haematol, 2020,
7(3): e226-e237., articleTitle=null, refAbstract=null), Reference(id=1327672230705738692, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=ZEISER R, VON BUBNOFF N, BUTLER J,
et al.Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease [J].
N Engl J Med, 2020,
382(19): 1800-1810., articleTitle=null, refAbstract=null), Reference(id=1327672230760264645, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.FDA approves ruxolitinib for acute graft-versus-host disease [EB/OL].(2019-05-24)[2022-03-04].
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ruxolitinib-acute-graft-versus-host-disease., articleTitle=null, refAbstract=null), Reference(id=1327672230839956422, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.FDA approves ruxolitinib for chronic graft-versus-host disease [EB/OL].(2021-09-22)[2022-03-04].
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ruxolitinib-chronic-graft-versus-host-disease., articleTitle=null, refAbstract=null), Reference(id=1327672230928036807, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=UPPAL S K, KEARNS D G, CHAT V S,
et al.Ruxolitinib cream for the treatment of vitiligo [J].
Lancet, 2020,
396(10264): 1735-1736., articleTitle=null, refAbstract=null), Reference(id=1327672230990951368, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.NDA 215309 approval(OPZELURA(ruxolitinib) cream)[EB/OL].(2019-05-24)[2022-03-04].
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/215309Orig1s000ltr.pdf., articleTitle=null, refAbstract=null), Reference(id=1327672231049671625, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.FDA approves drug for adults with rare form of bone marrow disorder [EB/OL].(2022-03-01)[2022-09-05].
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-adults-rare-form-bone-marrow-disorder., articleTitle=null, refAbstract=null), Reference(id=1327672231108391882, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=AHMED A, MERRILL S A, ALSAWAH F,
et al.Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial[J].
Lancet Haematol, 2019,
6(12): e630-e637., articleTitle=null, refAbstract=null), Reference(id=1327672232341517259, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=VERSTOVSEK S, MESA R A, GOTLIB J,
et al.A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis[J].
N Engl J Med, 2012,
366(9): 799-807., articleTitle=null, refAbstract=null), Reference(id=1327672232437986252, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=MASCARENHAS J, HOFFMAN R.Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis[J].
Clin Cancer Res, 2012,
18(11): 3008-3014., articleTitle=null, refAbstract=null), Reference(id=1327672232534455245, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=INCYTE CORP.Heteroaryl substituted pyrrolo[2,3-
b]-pyridines and pyrrolo[2,3-
b]pyrimidines as Janus kinase inhibitors: WO, 2007070514A1 [P].2006-12-12., articleTitle=null, refAbstract=null), Reference(id=1327672232630924238, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=INCYTE CORP.Salts of the janus kinases inhibitor (
R)-3-(4-(7
H-pyrrolo[2,3-
d]pyrimidin-4-yl)-1
H-pyrazol-1-yl)-3-cyclopentylpropanenitrile: WO, 2008157208A2 [P].2008-06-12., articleTitle=null, refAbstract=null), Reference(id=1327672232710616015, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=NI Y, PARIKH B, YELESWARAM K,
et al.Sustained-release dosage forms of ruxolitinib: WO, 2014078486A1[P].2013-11-14., articleTitle=null, refAbstract=null), Reference(id=1327672232819667920, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=VANNUCCHI A M, BOGANI C, GUGLIELMELLI P.mTOR/JAK inhibitor combination therapy: WO,2012112847A1 [P].2012-02-17., articleTitle=null, refAbstract=null), Reference(id=1327672232882582481, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=VANNUCCHI A M, BOGANI C, BARTALUCCI N.JAK P13K/mTOR combination therapy: WO, 2013023119A1[P].2012-08-10., articleTitle=null, refAbstract=null), Reference(id=1327672232962274258, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=INCYTE CORP.Treatment of B-cell malignancies by a combination JAK and PI3K δ inhibitor: WO, 2015157257A1[P].2015-04-07., articleTitle=null, refAbstract=null), Reference(id=1327672233016800211, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=INCYTE CORP.Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor: WO, 2021102258A1 [P].2020-11-20., articleTitle=null, refAbstract=null), Reference(id=1327672233079714772, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=STUBBS M, LIU P C.Combination of ruxolitinib with INCB057643 for treatment of myeloproliferative neoplasms: WO, 2021247064A1 [P].2020-09-14., articleTitle=null, refAbstract=null), Reference(id=1327672233146823637, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=HOWELL M D, SMITH P.Treatment of hidradenitis suppurativa using JAK inhibitors: WO, 2019191684A1[P].2019-03-29., articleTitle=null, refAbstract=null), Reference(id=1327672233218126806, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=SMITH P, WENZEL J.Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus(LP): WO, 2021076124A1 [P].2019-10-16., articleTitle=null, refAbstract=null), Reference(id=1327672233289429975, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=FRIEDMAN P A, FRIDMAN J S, LUCHI M E,
et al.Janus kinase inhibitors for treatment of dry eye and other eye related diseases: WO, 2010039939A1 [P].2009-10-01., articleTitle=null, refAbstract=null), Reference(id=1327672233352344536, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=CHRISTIANO A, CLYNES R.Methods and compositions for promoting hair growth: WO, 2016179605A1 [P].2016-05-09., articleTitle=null, refAbstract=null), Reference(id=1327672233423647705, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHOU J C, LIU P L, LIN Q Y,
et al.Processes for preparing JAK inhibitors and related intermediate compounds: WO,2010083283A2 [P].2010-01-14., articleTitle=null, refAbstract=null), Reference(id=1327672233486562266, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHOU J C, CHEN S L, LIU P L,
et al.Process and intermediates for preparing a JAK inhibitor: WO,2022040180A1 [P].2021-08-17., articleTitle=null, refAbstract=null), Reference(id=1327672233541088219, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=SILVERMAN I R, LIU J F, MORGAN A J,
et al.Deuterated derivatives of ruxolitinib: WO, 2013188783A1 [P].2013-06-14., articleTitle=null, refAbstract=null), Reference(id=1327672233604002780, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=TALPAZ M, KILADJIAN J J.Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis [J].
Leukemia, 2021,
35(1):1-17., articleTitle=null, refAbstract=null), Reference(id=1327672233687888861, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.INREBIC
®(fedratinib) capsules, for oral use[EB/OL].(2019-08-16)[2022-03-04].
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1327672233759192030, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=PARDANANI A, HARRISON C, CORTES J E,
et al.Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial [J].
JAMA Oncol, 2015,
1(5): 643-651., articleTitle=null, refAbstract=null), Reference(id=1327672233826300895, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=TARGEGEN INC.Bi-aryl meta-pyrimidine inhibitors of kinases: WO, 2007053452A1 [P].2006-10-16., articleTitle=null, refAbstract=null), Reference(id=1327672233893409760, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=IMPACT BIOMEDICINES INC.Crystalline forms of a JAK2 inhibitor: WO, 2020167844A1 [P].2020-02-11., articleTitle=null, refAbstract=null), Reference(id=1327672233960518625, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=HUANG L F, TSOU N, WU W J,
et al.Crystalline forms of a JAK2 inhibitor: WO, 2020167845A1 [P].2020-02-11., articleTitle=null, refAbstract=null), Reference(id=1327672234048599010, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=JOHNSON MATTHEY PLC.Novel forms of fedratinib dihydrochloride: US, 20210122718A1 [P].2020-10-29., articleTitle=null, refAbstract=null), Reference(id=1327672234132485091, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=TEFFERI A.Compositions and methods for treating myelofibrosis: WO, 2012060847A1 [P].2010-11-10., articleTitle=null, refAbstract=null), Reference(id=1327672234199593956, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=GRECO R, ADRIAN F.Compositions and methods of treating cancer using JAK2 inhibitor: WO, 2013059548A1[P].2012-10-19., articleTitle=null, refAbstract=null), Reference(id=1327672234266702821, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=HOOD J D.Method of treating thalassemia: WO,2010017122A2 [P].2009-08-03., articleTitle=null, refAbstract=null), Reference(id=1327672234329617382, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=null, refType=null, unstructuredReference=COHEN P, NEUMANN F.Compositions and methods for treating polycythemia vera and essential thrombocythemia: WO, 2013013195A1 [P].2012-07-20., articleTitle=null, refAbstract=null), Reference(id=1327672234430280679, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[53], rfOrder=52, authorNames=null, journalName=null, refType=null, unstructuredReference=GERIKE T G, RIZO A.Methods of treating myeloproliferative disorders: WO, 2020068754A1 [P].2018-09-25., articleTitle=null, refAbstract=null), Reference(id=1327672234509972456, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[54], rfOrder=53, authorNames=null, journalName=null, refType=null, unstructuredReference=BERRY T, HOOD J, JAMIESON C,
et al.Methods of treating myeloproliferative disorders: WO, 2020068755A1[P].2019-09-24., articleTitle=null, refAbstract=null), Reference(id=1327672234581275625, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[55], rfOrder=54, authorNames=null, journalName=null, refType=null, unstructuredReference=MALDONADO M A, BANERJEE S, KELLY S M,
et al.Methods of treating acute respiratory disorders: WO,2021207051A1 [P].2021-04-05., articleTitle=null, refAbstract=null), Reference(id=1327672234669356010, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[56], rfOrder=55, authorNames=null, journalName=null, refType=null, unstructuredReference=MESA R A, VANNUCCHI A M, MEAD A,
et al.Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias(PERSIST-1): an international, randomised, phase 3 trial [J].
Lancet Haematol, 2017,
4(5): e225-e236., articleTitle=null, refAbstract=null), Reference(id=1327672234761630699, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[57], rfOrder=56, authorNames=null, journalName=null, refType=null, unstructuredReference=MASCARENHAS J, HOFFMAN R, TALPAZ M,
et al.Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial [J].
JAMA Oncol, 2018,
4(5): 652-659., articleTitle=null, refAbstract=null), Reference(id=1327672234832933868, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[58], rfOrder=57, authorNames=null, journalName=null, refType=null, unstructuredReference=SUZUKI S, TSUDA K, TANIMOTO T.Pacritinib in patients with myelofibrosis [J].
JAMA Oncol, 2018,
4(12):1786-1787., articleTitle=null, refAbstract=null), Reference(id=1327672234891654125, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[59], rfOrder=58, authorNames=null, journalName=null, refType=null, unstructuredReference=BLANCHARD S, LEE C H A, NAGARAJ H K M,
et al.Oxygen linked pyrimidine derivatives: WO, 2007058627A1[P].2006-11-15., articleTitle=null, refAbstract=null), Reference(id=1327672234967151598, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[60], rfOrder=59, authorNames=null, journalName=null, refType=null, unstructuredReference=DYMOCK B, LEE C H A, WILLIAM A D.11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19,3,1,1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt: WO,2010068181A1 [P].2009-12-09., articleTitle=null, refAbstract=null), Reference(id=1327672235046843375, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[61], rfOrder=60, authorNames=null, journalName=null, refType=null, unstructuredReference=BETTS B C, YU X, ANASETTI C.Methods of treating transplant rejection: WO, 2017058950A1 [P].2016-09-28., articleTitle=null, refAbstract=null), Reference(id=1327672235134923760, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[62], rfOrder=61, authorNames=null, journalName=null, refType=null, unstructuredReference=BHATNAGAR B, BAKER S D.Methods of treating FLT3-mutated hematologic cancers: EP, 3860655A1 [P].2019-10-01., articleTitle=null, refAbstract=null), Reference(id=1327672235206226929, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[63], rfOrder=62, authorNames=null, journalName=null, refType=null, unstructuredReference=许学农.帕克替尼的制备方法:中国,105017282A [P].2015-08-28., articleTitle=null, refAbstract=null), Reference(id=1327672235290113010, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[64], rfOrder=63, authorNames=null, journalName=null, refType=null, unstructuredReference=许学农,薛佳,王喆,等.一种帕克替尼的制备方法:中国,105061467A [P].2015-08-28., articleTitle=null, refAbstract=null), Reference(id=1327672235344638963, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[65], rfOrder=64, authorNames=null, journalName=null, refType=null, unstructuredReference=刘耿熙,陈兰华,季辉,等.一种有机硅担载的离子液体催化制备药物中间体的方法:中国,108623535A [P].2018-06-25., articleTitle=null, refAbstract=null), Reference(id=1327672235415942132, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[66], rfOrder=65, authorNames=null, journalName=null, refType=null, unstructuredReference=HARBESON S L.Deuterated pacritinib: WO,2014159511A1 [P].2014-03-12., articleTitle=null, refAbstract=null), Reference(id=1327672235524994037, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[67], rfOrder=66, authorNames=null, journalName=null, refType=null, unstructuredReference=黄璐,古双喜,洪怡.选择性转染重排酪氨酸激酶抑制剂概述及其专利研究[J].中国医药工业杂志,2021,
52(10):1291-1296., articleTitle=null, refAbstract=null), Reference(id=1327672235592102902, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[68], rfOrder=67, authorNames=null, journalName=null, refType=null, unstructuredReference=HUANG T S, XUE C B, WANG A,
et al.Piperidin-4-yl azetidine derivatives as JAK1 inhibitors: WO, 2011112662A1[P].2011-03-09., articleTitle=null, refAbstract=null), Reference(id=1327672235671794679, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[69], rfOrder=68, authorNames=null, journalName=null, refType=null, unstructuredReference=BURNS C J, DONOHUE A C, FEUTRILL J T,
et al.Phenyl amino pyrimidine compounds and uses thereof: WO,2008109943A1 [P].2008-03-12., articleTitle=null, refAbstract=null), Reference(id=1327672235743097848, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[70], rfOrder=69, authorNames=null, journalName=null, refType=null, unstructuredReference=LV B H, SHENG Z L, CAO B W.Deuterated phenyl amino pyrimidine compound and pharmaceutical composition containing same: WO, 2014114274A1 [P].2014-01-28., articleTitle=null, refAbstract=null), Reference(id=1327672235814401017, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[71], rfOrder=70, authorNames=null, journalName=null, refType=null, unstructuredReference=黄璐,钱丽娜,张晓瑜,等.医药领域的专利保护与专利布局策略[J].中国新药杂志,2017,
26(2):139-144., articleTitle=null, refAbstract=null), Reference(id=1327672235885704186, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[72], rfOrder=71, authorNames=null, journalName=null, refType=null, unstructuredReference=国家知识产权局.中华人民共和国专利法(2020年修正)[EB/OL].(2020-11-23)[2022-05-08].
https://www.cnipa.gov.cn/art/2020/11/23/art_97_155167.html., articleTitle=null, refAbstract=null), Reference(id=1327672235948618747, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[73], rfOrder=72, authorNames=null, journalName=null, refType=null, unstructuredReference=中华人民共和国中央人民政府.国家药监局国家知识产权局关于发布《药品专利纠纷早期解决机制实施办法(试行)》的公告(2021年第89号)[EB/OL].(2021-07-04)[2022-05-08].
http://www.gov.cn/zhengce/zhengceku/2021-07/04/content_5622330.htm., articleTitle=null, refAbstract=null), Reference(id=1327672236011533308, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[74], rfOrder=73, authorNames=null, journalName=null, refType=null, unstructuredReference=中华人民共和国最高人民法院.最高人民法院关于审理申请注册的药品相关的专利权纠纷民事案件适用法律若干问题的规定[EB/OL].(2021-07-04)[2022-05-08].
https://www.court.gov.cn/zixun-xiangqing-311791.html., articleTitle=null, refAbstract=null)], funds=[Fund(id=1327672229472613298, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, awardId=18BFX168, language=CN, fundingSource=国家社会科学基金项目(专利到期药物仿制上市法律保障机制研究(18BFX168), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1327672225651602302, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, xref=1., ext=[AuthorCompanyExt(id=1327672225659990911, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225651602302, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205), AuthorCompanyExt(id=1327672225668379520, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225651602302, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.武汉工程大学化工与制药学院,湖北 武汉 430205)]), AuthorCompany(id=1327672225727099777, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, xref=2., ext=[AuthorCompanyExt(id=1327672225735488386, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225727099777, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.School of Pharmacutical Sciences, Wuhan University, Wuhan 430071), AuthorCompanyExt(id=1327672225739682691, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225727099777, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.武汉大学药学院,湖北 武汉 430071)]), AuthorCompany(id=1327672225785820036, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, xref=3., ext=[AuthorCompanyExt(id=1327672225794208645, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225785820036, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
3.Guangzhou Wellhealth Bio-pharma Co., Ltd., Guangzhou 510200), AuthorCompanyExt(id=1327672225802597254, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225785820036, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
3.广州丹康医药生物有限公司,广东 广州 510200)]), AuthorCompany(id=1327672225848734599, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, xref=4., ext=[AuthorCompanyExt(id=1327672225857123208, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225848734599, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
4.Kanazawa Institute of Technology, Tokyo 105-0002, Japan), AuthorCompanyExt(id=1327672225861317513, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225848734599, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
4.金泽工业大学大学院,日本 东京都 105-0002)]), AuthorCompany(id=1327672225920037770, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, xref=5., ext=[AuthorCompanyExt(id=1327672225928426379, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225920037770, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
5.Dept. of Pathology, Hubei Cancer Hospital, Wuhan 430079), AuthorCompanyExt(id=1327672225936814988, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225920037770, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
5.湖北省肿瘤医院病理科,湖北 武汉 430079)]), AuthorCompany(id=1327672225991340941, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, xref=6., ext=[AuthorCompanyExt(id=1327672225999729550, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225991340941, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
6.FIWIS Intellectual Property Law Firm, Beijing 100032), AuthorCompanyExt(id=1327672226008118159, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672224779187067, companyId=1327672225991340941, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
6.北京孚睿湾知识产权代理事务所,北京 100032)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li {
margin-right: 18px;
}
@media (max-width: 1442px) {
.style-1 .main-menu ul>li a {
font-size: 16px;
padding: 10px 0;
}
}, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li {
margin-right: 18px;
}
@media (max-width: 1442px) {
.style-1 .main-menu ul>li a {
font-size: 16px;
padding: 10px 0;
}
}, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2022.10.005, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2022.10.005, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2022.10.005, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2022.10.005, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1665331200000, fullTextJson=null, articleText=null, reference=null)